Overview

Treatment of Pain Associated With Fibromyalgia

Status:
Completed
Trial end date:
2017-01-12
Target enrollment:
Participant gender:
Summary
The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in participants receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the subject that best describes his or her worst pain over the previous 24 hours.
Phase:
Phase 3
Details
Lead Sponsor:
Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.
Collaborators:
INC Research
Syneos Health
Treatments:
Pregabalin